Cidara Therapeutics/ US1717571079 /
| 7/6/2022 9:52:24 PM | Chg. +0.06 | Volume | Bid- | Ask- | High | Low |
|---|---|---|---|---|---|---|
| 0.53USD | +11.85% | 1,990 Turnover: 1,027.25 |
-Bid Size: - | -Ask Size: - | 0.54 | 0.49 |
GlobeNewswire
3/7
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financia...
GlobeNewswire
2/14
Cidara Therapeutics Announces FDA Acceptance of its Investigational New Drug Application for CD388 f...
GlobeNewswire
1/6
Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
12/14/2021
Cidara Therapeutics and Mundipharma Announce Positive Topline Results from the Global Phase 3 Pivota...
GlobeNewswire
11/22/2021
Cidara Therapeutics Named A San Diego Metro Area Top Workplace For The Fifth Consecutive Year
GlobeNewswire
11/10/2021
Cidara Provides Corporate Update and Reports Third Quarter 2021 Financial Results
GlobeNewswire
10/13/2021
Cidara Therapeutics Announces Closing of Concurrent Public Offerings of Common Stock and Preferred S...
GlobeNewswire
10/8/2021
Cidara Therapeutics Announces Pricing of Concurrent Public Offerings of Common Stock and Preferred S...
GlobeNewswire
10/7/2021
Cidara Therapeutics Announces Commencement of Concurrent Public Offerings of Common Stock and Prefer...
GlobeNewswire
10/1/2021
Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
9/1/2021
Cidara Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Financial Officer and Chief Business...
GlobeNewswire
8/17/2021
Cidara Therapeutics and Mundipharma Announce Completion of Enrollment in the Phase 3 ReSTORE Trial o...
GlobeNewswire
8/12/2021
Cidara Provides Corporate Update and Reports Second Quarter 2021 Financial Results
GlobeNewswire
8/5/2021
Cidara Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference
GlobeNewswire
7/27/2021
Cidara Therapeutics to Present New Data for Rezafungin at the International Society for Human and An...
GlobeNewswire
7/12/2021
Cidara Therapeutics Presents New Analyses from Multiple Rezafungin Studies at ECCMID 2021
GlobeNewswire
7/7/2021
Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
6/30/2021
Cidara Therapeutics to Present New Analyses for Rezafungin at the 31st European Congress of Clinical...
GlobeNewswire
6/14/2021
Cidara Therapeutics to Participate in the Raymond James Human Health Innovation Conference